Researchers conducted an immunohistochemical analysis of 702 human breast cancer cases (with a median follow-up time of 8 years) and found that surface membrane-localized and mature glycosylated Trop-2 is associated with poorer patient survival, while intracellular retention of Trop-2 is linked to fewer disease recurrences and better survival outcomes (37). Here, TACSTD2 is linked to breast cancer.